Novo, Gurnet Point wrap up $462m acquisition of Paratek Pharmaceuticals
The flagship product of Paratek Pharmaceuticals is Nuzyra (omadacycline), an oral and intravenous antibiotic approved for use in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Sep 23
The flagship product of Paratek Pharmaceuticals is Nuzyra (omadacycline), an oral and intravenous antibiotic approved for use in…
22 Sep 23
The merged entity will initially focus to advance Cyclo’s Phase 3 global TransportNPC study that is evaluating investigational…
22 Sep 23
FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for 7 years of U.S. market exclusivity after approval
21 Sep 23
The approval was supported by data from the Phase 3 EMERALD trial in which Orserdu showed statistically significant…
21 Sep 23
On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in…
20 Sep 23
Co-developed by Japan-based Otsuka and British Astex, Inaqovi has been cleared by EC as monotherapy in AML patients…
20 Sep 23
Tevimbra is a humanised IgG4 anti-PD-1 monoclonal antibody designed to lower binding to Fc-gamma (Fcγ) receptors on macrophages,…
20 Sep 23
GT Molecular, Inc., a company providing ultrasensitive PCR assays for wastewater-based epidemiology testing, pathogen detection, and cancer research…
20 Sep 23
Rhythm is evaluating setmelanotide in a global Phase 3 clinical trial in acquired hypothalamic obesity and expects to…
20 Sep 23
Acceptance based on results from the Phase 3 LITESPARK-005 trial, which showed a statistically significant and clinically meaningful…